Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

OMER 11.11.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-13
Name of Upcoming Event:Omeros’ conference call
Full Press ReleaseSEC FilingsOur OMER Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
  • 12.19.2024 - Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
  • 12.10.2024 - Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Recent Filings

  • 01.16.2025 - 8-K Current report
  • 01.16.2025 - EX-99.1 EX-99.1
  • 11.13.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]

SEATTLE--(BUSINESS WIRE)--Nov. 11, 2024--Omeros Corporation(NASDAQ: OMER), today announced that the company will issue its financial results for the quarter endedSeptember 30, 2024, onWednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at4:30 p.m. Eastern Time(1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Conference Call Details

For online access to the live webcast of the conference call, go to Omeros’ website athttps://investor.omeros.com/upcoming-events.

To access the live conference call via phone, participants must register atthis linkto receive a unique PIN.Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the “Call Me” option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN.

A replay of the call will be made accessible online athttps://investor.omeros.com/archived-events.

AboutOmeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by theNational Institute on Drug Abuse, Omeros’ lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of five novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visitwww.omeros.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241111830029/en/

Jennifer Cook WilliamsCookWilliams Communications, Inc.Investor and Media RelationsIR@omeros.com

Source:Omeros Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com